CA-DEXERIALS
Dexerials Corporation, (TOKYO: 4980) (Headquarters: Shimotsuke-shi, Tochigi, Representative Director and President: Yoshihisa Shinya, hereinafter “Dexerials”), which provides leading-edge technologies, materials, and devices for smartphones, automobiles, and other products, announces that the name of the integrated company to be created under Dexerials Precision Components Corporation (Headquarters: Tome-shi, Miyagi, Hereinafter “DXPC”) and Kyoto Semiconductor Co., Ltd. (Headquarters: Shimotsuke-shi, Tochigi, hereinafter “Kyoto Semiconductor”) has been determined as Dexerials Photonics Solutions Corporation (hereinafter “DXPS”), a consolidated subsidiary of Dexerials in Japan, and that DXPS will commence operation on April 1, 2024. In accordance with Dexerials’ news release on July 31, 2023, entitled Notice Regarding Launch of Integrated Company to Lead Growth in the Photonics Domain, preparations for a launch of the integrated company between DXPC and Kyoto Semiconductor had been made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321222931/en/
Change in sales structure after the launch of DXPS (Graphic: Business Wire)
The profile of DXPS is as follows.
Profile of the integrated company
Corporate name |
Dexerials Photonics Solutions Corporation |
Head office |
Shimotsuke-shi, Tochigi |
Offices |
Eniwa Operation, Kamisunagawa Operation and Tome Operation |
Date of inauguration |
April 1, 2024 |
Share capital |
100 million yen |
Representative (planned) |
Kazuya Hayashibe, Representative Director and President |
Business |
Development, production and production management of optical semiconductors, optical devices and semiconductor-composite devices (photonics products) |
Dexerials Group will support DXPS in developing and providing solutions essential to the evolution of technologies in the photonics domain, aiming to increase efficiency in society. In so doing, the Group will help build a sustainable society, while aiming to achieve continuous growth and higher corporate value.
DXPS will develop and manufacture** microdevices and optical semiconductor device products that have been operated by DXPC and Kyoto Semiconductor. Dexerials will sell them to customers as its photonics products.
Dexerials and Kyoto Semiconductor will participate as an exhibitor at the OFC 2024 trade show that will take place at the San Diego Convention Center in San Diego in the United States from Tuesday, March 26 to Thursday, March 28. We cordially invite visitors to the exhibition to drop by our booth.
Comment from Kazuya Hayashibe, Representative Director and President (planned), DXPS
The Dexerials Group has been effectively combining technologies with the knowledge possessed by its human resources to offer materials and solutions indispensable to electronics and automobiles, aiming to link them to the evolution of digital technologies.
In the future, artificial intelligence (AI), Internet of things (IoT), next-generation communication and other new technologies will have increasing opportunities to play significant roles in boosting the efficiency of society for solving social issues. It is hence anticipated that optical semiconductors and the photonics solutions that support them will also have greater roles to play.
DXPS will lead the Dexerials Group’s business growth in the photonics domain. It will combine the optical semiconductor technologies cultivated by Kyoto Semiconductor, one of its predecessors, with the Dexerials Group’s technologies of controlling light and electricity to create unprecedented photonics solutions and to help resolve social issues. This will be the reason for its existence and it will tackle its work with a strong determination.
Dexerials and Kyoto Semiconductor will showcase their products and present the integrated company, DXPS, in their booth at the OFC 2024 exhibition that will start on March 26 in San Diego in the United States. We cordially invite visitors to the exhibition to drop by our booth. We look forward to seeing you at San Diego.
Change in sales structure after the launch of DXPS
Please see the diagram.
(Notes) |
* DXPC, Kyoto Semiconductor and DXPS are wholly owned subsidiaries of Dexerials Corporation. |
|
** After the launch of DXPS, OSDC will continue to manufacture microdevices under contract. |
|
*** Photonics products correspond to products that have been handled by DXPC and Kyoto Semiconductor. |
Participation in the OFC 2024 exhibition in San Diego, USA
OFC 2024 Exhibition
Date: Tuesday, March 26, 2024 to Thursday, March 28, 2024
Venue: San Diego Convention Center (San Diego, USA)
Stand number: 3814
Official website: https://www.ofcconference.org/en-us/home/
Products to be displayed
1. Optical semiconductor
2. Inorganic waveplate
3. Smart precision Adhesive
4. Anisotropic Conductive Film (ACF)
About Dexerials Corporation https://www.dexerials.jp/en/
Dexerials Corporation is a manufacturer providing functional materials for use in smartphones, automobiles and other domains in accordance with its corporate vision, Value Matters - Unprecedented innovation, unprecedented value. On a global scale, Dexerials Corporation manufactures and markets Anisotropic Conductive Film (ACF), optical elastic resin (SVR), anti-reflection film, surface mounted type fuses, industrial adhesives, double- and single-sided tapes and other electronic parts, junction materials, optical materials, and many other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321222931/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
